FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
2018; Massachusetts Medical Society; Volume: 379; Issue: 25 Linguagem: Inglês
10.1056/nejmoa1809775
ISSN1533-4406
AutoresThierry Conroy, Pascal Hammel, Mohamed Hebbar, Méher Ben Abdelghani, Alice C. Wei, Jean‐Luc Raoul, Laurence Choné, E. François, Pascal Artru, James Biagi, Thierry Lecomte, Éric Assenat, Roger Faroux, Marc Ychou, Julien Volet, Alain Sauvanet, Gilles Breysacher, Frédéric Di Fiore, C. Cripps, Petr Kavan, Patrick Texereau, Karine Bouhier‐Leporrier, Faiza Khemissa-Akouz, Jean-Louis Legoux, Béata Juzyna, Sophie Gourgou, Christopher J. O’Callaghan, Claire Jouffroy-Zeller, Patrick Rat, David Malka, Florence Castan, Jean‐Baptiste Bachet,
Tópico(s)Renal cell carcinoma treatment
ResumoAmong patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.
Referência(s)